ea0068p11 | Abstracts | UKINETS2019
Hazeldine Thomas
, Braimah Fatimah
, Brown Peter
, Anthoney Alan
Introduction: Somatostatin analogues (SSA) are a cornerstone in the treatment of neuroendocrine tumours. Two clinical trials have defined the disease control effect of these treatments; the PROMID study of Octreotide LAR vs placebo, median time to tumour progression (TTP) 14.2 m vs 6.0 m, and the CLARINET study (Lanreotide vs placebo), median progression free survival (PFS) 31 m vs 18 m. In every day practice, however, many neuroendocrine tumours commen...